NeuShen Therapeutics
Website unreachable since Oct 21, 2026
NeuShen Therapeutics develops CNS-tropic AAV gene therapies and small molecule treatments to address severe neurological and psychiatric disorders, including schizophrenia and depression. Their proprietary NeuGem™ platform focuses on efficient gene delivery, while the NeuChime™ platform utilizes AI-assisted drug discovery to create novel therapeutic options for patients with limited existing treatments.
- Biotechnology
Funding
Founders
Product
Problem
Many neurological and psychiatric disorders lack effective treatments, leaving millions of patients with limited options. Existing therapies often have significant side effects or fail to address the underlying causes of these complex conditions. The development of new treatments for central nervous system (CNS) disorders is hampered by the difficulty of delivering drugs and gene therapies effectively to the brain.
Solution
NeuShen Therapeutics is developing novel gene therapies and small molecule treatments for severe neurological and psychiatric disorders. Their NeuGem™ platform focuses on designing CNS-tropic adeno-associated virus (AAV) capsids and gene expression cassettes to improve the efficiency, effectiveness, and safety of gene therapies. The NeuChime™ platform utilizes artificial intelligence (AI) to accelerate the discovery of small molecule drugs with novel mechanisms of action. These platforms aim to create innovative therapeutic options for patients with conditions like schizophrenia and depression, where current treatments are inadequate.
Target Audience
The primary target audience includes patients suffering from severe neurological and psychiatric disorders, such as schizophrenia and depression, and the healthcare professionals who treat them.
Features
- NeuGem™ AAV Gene Therapy Platform:
- Novel CNS-tropic AAV capsid engineering for efficient and specific delivery to the central nervous system.
- Advanced expression cassette construction to address complex pathologies observed in CNS diseases.
- NeuChime™ Small Molecule Discovery Platform:
- Combines traditional small molecule drug discovery with AI-assisted technologies to improve efficiency and innovation.
- Focus on new mechanism treatments for psychiatric disorders with faster onset, better long-term disease control, and more favorable side effect profiles.
- Pipeline includes programs targeting psychiatric disorders, with plans to enter IND-enabling development.
- NS-136: A novel selective M4 receptor positive allosteric modulator for the treatment of schizophrenia currently in a first-in-human trial.
- Highly Selective KCNQ2/3 Activator: Received NMPA-CDE IND approval.